We previously reported that on December 21, 2017, Genentech filed suit against Sandoz in the District of New Jersey based on Sandoz’s proposed rituximab biosimilar, Rixathon/GP2013.  On April 24, 2018, Judge Renee Marie Bumb held an in-person status conference and set forth a preliminary injunction briefing schedule.  She ordered the motion for preliminary injunction to be filed by May 4, 2018, opposition to be filed by June 4, 2018 and any reply to be filed by June 29, 2018.

We will continue to monitor this litigation.  Stay tuned to Big Molecule Watch for further updates.